Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/58743
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12642]
Metadatos
Mostrar el registro completo del ítem
THE EFFECTIVENESS OF COVID-19 VACCINES IN LATIN AMERICA, 2021: A MULTICENTER REGIONAL CASE–CONTROL STUDY
Eficácia da vacina
Controle de caso
Teste negativo
Brasil
Chile
Argentina
Colômbia
Vaccine effectiveness
Case–control
Test-negative
Brazil
Chile
Argentina
Colombia
Autor
Afiliación
Harvard TH Chan School of Public Health, 677 Huntington Ave Suite 506, Boston, MA, 02115, USA.
University of Michigan, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA.
Harvard TH Chan School of Public Health. Boston, MA, 02115, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais. Rio de Janeiro, RJ, Brasil.
SMDB conjunto 12b lote 3 Casa B. Brasília DF, Brasil.
Harvard TH Chan School of Public Health. Boston, MA, 02115, USA.
Immunization Unit, Pan American Health Organization, Washington, USA.
Universidade Federal de Goiás. Instituto de Patologia Tropical e Saúde Pública. Goiânia, GO, Brasil.
Immunization Unit, Pan American Health Organization, Washington, USA.
University of Michigan, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA.
Harvard TH Chan School of Public Health. Boston, MA, 02115, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais. Rio de Janeiro, RJ, Brasil.
SMDB conjunto 12b lote 3 Casa B. Brasília DF, Brasil.
Harvard TH Chan School of Public Health. Boston, MA, 02115, USA.
Immunization Unit, Pan American Health Organization, Washington, USA.
Universidade Federal de Goiás. Instituto de Patologia Tropical e Saúde Pública. Goiânia, GO, Brasil.
Immunization Unit, Pan American Health Organization, Washington, USA.
Resumen en ingles
Summary
Background As of September 2022, nearly 1.3 billion doses of COVID-19 vaccine products have been administered in
Latin America and the Caribbean, where 27% of global COVID-19 deaths have occurred. This study aimed to estimate
the effectiveness of COVID-19 vaccines against lab-confirmed COVID-19 related hospitalizations and deaths among
adults in Argentina, Brazil, Chile, and Colombia.
Methods Using a test-negative case control design, we evaluated the effectiveness of a primary vaccination series
considering six COVID-19 vaccine products (Sputnik V, mRNA-1273, CoronaVac, ChAdOx1, BNT162b2,
Ad26.COV2.S) against lab-confirmed COVID-19 hospitalizations and deaths among 83,708 hospitalized adults
from February–December, 2021. Data from hospitalization records, COVID surveillance, and vaccination registries
were used. Vaccine effectiveness was estimated using logistic regression ((1-OR) x 100).
Findings The average age of participants was 56.7 (SD = 17.5), and 45,894 (54.8%) were male. Adjusted VE (aVE)
estimates for full vaccination against hospitalization were 82% for mRNA-1273 (95% confidence interval (CI) = −30 to
98%), 76% (71%–81%) for BNT162b2, 65% (61–68%) for ChAdOx1, 57% (10–79%) for Sputnik V, 53% (50–56%) for
CoronaVac, and 46% (23–62%) for Ad26.COV2.S. Estimates, particularly for CoronaVac, varied by variant.
Decreasing aVE was estimated as age increased, particularly for CoronaVac and ChAdOx1. aVE estimates against
death were generally higher, with 100% (CI not estimated) for mRNA-1273, 82% (69–90%) for BNT162b2, 73%
(69–77%) for ChAdOx1, 65% (60–67%) for CoronaVac, 38% (−75 to 78%) for Sputnik V, 6% (−58 to 44%) for
Ad26.COV2.S.
Palabras clave en portugues
Vacinação COVID-19Eficácia da vacina
Controle de caso
Teste negativo
Brasil
Chile
Argentina
Colômbia
Palabras clave en ingles
COVID-19 vaccinationVaccine effectiveness
Case–control
Test-negative
Brazil
Chile
Argentina
Colombia
Compartir